MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging
- PMID: 34824477
- PMCID: PMC8916956
- DOI: 10.1038/s41592-021-01308-y
MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging
Abstract
Highly multiplexed tissue imaging makes detailed molecular analysis of single cells possible in a preserved spatial context. However, reproducible analysis of large multichannel images poses a substantial computational challenge. Here, we describe a modular and open-source computational pipeline, MCMICRO, for performing the sequential steps needed to transform whole-slide images into single-cell data. We demonstrate the use of MCMICRO on tissue and tumor images acquired using multiple imaging platforms, thereby providing a solid foundation for the continued development of tissue imaging software.
© 2021. The Author(s).
Conflict of interest statement
P.K.S. is a member of the SAB or BOD member of Applied Biomath, RareCyte Inc. and Glencoe Software, which distributes a commercial version of the OMERO database; P.K.S. is also a member of the NanoString SAB. In the last 5 years, the Sorger laboratory has received research funding from Novartis and Merck. Sorger declares that none of these relationships have influenced the content of this manuscript. S. Santagata is a consultant for RareCyte Inc. A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and, until 31 July 2020, was an SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. Since 1 August 2020, A.R. has been an employee of Genentech. L.M.C. is a paid consultant for Cell Signaling Technologies, AbbVie Inc. and Shasqi Inc.; received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., Innate Pharma, NanoString Technologies and Cell Signaling Technologies; is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc., Verseau Therapeutics, Cytomix Therapeutics, Inc. and Kineta Inc. and is a member of the Lustgarten Therapeutics Advisory working group. D.S. is a consultant for Roche Glycart AG. The other authors declare no outside interests.
Figures


References
Publication types
MeSH terms
Grants and funding
- U54 CA225088/CA/NCI NIH HHS/United States
- R21 HD099367/HD/NICHD NIH HHS/United States
- U01 CA224012/CA/NCI NIH HHS/United States
- R35 CA197570/CA/NCI NIH HHS/United States
- R01 CA223150/CA/NCI NIH HHS/United States
- U2C CA233280/CA/NCI NIH HHS/United States
- U2C CA233262/CA/NCI NIH HHS/United States
- U2C CA233291/CA/NCI NIH HHS/United States
- R50 CA252138/CA/NCI NIH HHS/United States
- P50 CA236733/CA/NCI NIH HHS/United States
- K99 CA256497/CA/NCI NIH HHS/United States
- P30 CA006516/CA/NCI NIH HHS/United States
- R01 CA226909/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical